Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 2, 2003, Pages 120-126

  Ntais, Christos ^a   Polycarpou, Anastasia ^a   Ioannidis, John P A ^a,b,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450C17; GENE PRODUCT;

ALLELISM; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RISK FACTOR;

AFRICA; AGE FACTORS; ALLELES; ASIA; CASE-CONTROL STUDIES; EUROPE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; STATISTICS; STEROID 17-ALPHA-HYDROXYLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0037320659     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., and Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer. Inst. (Bethesda), 88: 1118-1126, 1996.
2. Makridakis, N. M., and Reichardt, J. K. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol. Rev., 23: 24-29, 2001.
3. Picado-Leonard, J., and Miller, W. L. Cloning and sequence of the human gene for P450c17 (steroid 17 α-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA (N. Y.), 6: 439-448, 1987.
4. Carey, A. H., Waterworth, D., Patel, K., White, D., Little, J., Novelli, P., Franks, S., and Williamson, R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet., 3: 1873-1876, 1994.
5. Nedelcheva Kristensen, V., Haraldsen, E. K., Anderson, K. B., Lonning, P. E., Erikstein, B., Karesen, R., Gabrielsen, O. S., and Borresen-Dale, A. L. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res., 59: 2825-2828, 1999.
6. Lunn, R. M., Bell, D. A., Mohler, J. L., and Taylor, J. A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (Lond.), 20: 1727-1731, 1999.
7. Gsur, A., Bernhofer, G., Hinteregger, S., Haidinger, G., Schatzl, G., Madersbacher, S., Marberger, M., Vutuc, C., and Micksche, M. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int. J. Cancer, 87: 434-437, 2000.
8. Yamada, Y., Watanabe, M., Murata, M., Yamanaka, M., Kubota, Y., Ito, H., Katoh, T., Kawamura, J., Yatani, R., and Shiraishi, T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP-17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int. J. Cancer, 92: 683-686, 2001.
9. Haiman, C. A., Stampfer, M. J., Giovannuci, E., Ma, J., Decalo, N. E., Kantoff, P. W., and Hunter, D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol. Biomark. Prev., 10: 743-748, 2001.
10. Kittles, R. A., Panguluri, R. K., Chen, W., Massac, A., Ahaghotu, C., Jackson, A., Ukoli, F., Adams-Campbell, L., Isaacs, W., and Dunston, G. M. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol. Biomark. Prev., 10: 943-947, 2001.
11. Stanford, J. L., Noonan, E. A., Iwasaki, L., Kolb, S., Chadwick, R. B., Feng, Z., and Ostrander, E. A. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol. Biomark. Prev., 11: 243-247, 2002.
12. Chang, B. I., Zheng, S. L., Issacs, S. D., Wiley, K. E., Carpten, J. D., Hawkins, G. A., Bleecker, E. R., Walsh, P. C., Trent, J. M., Meyers, D. A., Isaacs, W. B., and Xu, J. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int. J. Cancer, 95: 354-359, 2001.
13. Latil, A. G., Azzouzi, R., Cancel, G. S., Guillaume, E. C., Cochan-Priollet, B., Berthon, P. L., and Cussenot, O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer (Phila.), 92: 1130-1137, 2001.
14. Wadelius, M., Andersson, A. O., Johansson, J. E., Wadelius, C., and Rane, E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics, 9: 635-639, 1999.
15. Habuchi, T., Liqing, Z., Suzuki, T., Sasaki, R., Tsuchiya, N., Tachiki, H., Shimoda, N., Satoh, S., Sato, K., Kakehi, Y., Kamoto, T., Ogawa, O., and Kato, T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res., 60: 5710-5713, 2000.
16. Lau, J., Ioannidis, J. P., and Schmid, C. H. Quantitative synthesis in systematic reviews. Ann. Intern. Med., 127: 820-826, 1997.
17. Petitti, D. B. Meta-analysis, decision analysis, and cost-effectiveness analysis. New York: Oxford University Press, 1994.
18. Lau, J., Antman, E. M., Jimenez-Silva, J., Kupelnick, B., Mosteller, F., and Chalmers, T. C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N. Engl. J. Med., 327: 248-254, 1992.
19. Ioannidis, J. P., Contopoulos-Ioannidis, D. G., and Lau, J. Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. J. Clin. Epidemiol., 52: 281-291, 1999.
20. Ioannidis, J. P., and Lau, J. Evolution of treatment effects over time: empirical insight from recursive cumulative meta-analyses. Proc. Natl. Acad. Sci. USA, 98: 831-836, 2001.
21. Begg, C. B., and Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 50: 1088-1101, 1994.
22. Easterbrook, P. J., Berlin, J. A., Gopalan, R., and Matthews, D. R. Publication bias in clinical research. Lancet, 337: 867-872, 1991.
23. Ioannidis, J. P. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. J. Am. Med. Assoc., 279: 281-286, 1998.
24. Cotter, M. P., Gem, R. W., Ho, G. Y., Chang, R. Y., and Burk, R. D. Role of family history and ethnicity on the mode and age of prostate cancer presentation. Prostate, 50: 216-221, 2002.
25. Hoffman, R. M., Gilliard, F. D., Eley, J. W., Harlan, L. C., Stephenson, R. A., Stanford, J. L., Albertson, P. C., Hamilton, A. S., Hunt, W. C., and Potosky, A. L. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J. Natl. Cancer Inst. (Bethesda), 93: 388-395, 2001.
26. Thompson, I., Tangen, C., Tolcher, A., Crawford, E., Eisenberger, M., and Moinpour, C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J. Natl. Cancer Inst. (Bethesda), 93: 219-225, 2001.
27. Platz, E. A., Rimm, E. B., Willett, W. C., Kantoff, P. W., and Giovanucci, E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J. Natl. Cancer Inst. (Bethesda), 92: 2009-2017, 2000.
28. Feigelson, H. S., McKean-Cowdin, R., Pike, M. C., Coetzee, G. A., Kolonel, L. N., Nomura, A. M., Le Marchand, L., and Henderson, B. E. Cytochrome P450c17α gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res., 59: 3908-3910, 1999.
29. Zmuda, J. M., Cauley, J. A., Kuller, L. H., and Ferrell, R. E. A common promotor variant in the cytochrome P450c17α (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. J. Bone Miner. Res., 16: 911-917, 2001.
30. Allen, N. E., Forrest, M. S., and Key, T. J. The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol. Biomark. Prev., 10: 185-189, 2001.
31. Gharani, N., Waterworth, D. M., Williamson, R., and Franks, S. 5′ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J. Clin. Endocrinol. Metab., 81: 4174, 1996.
32. Berstein, L. M., Imyanitov, E. N., Gamajunova, V. B., Kovalevskij, A. J., Kuligina, E. Sh., Belogubova, E. V., Buslov, K. G., Karpova, M. B., Togo, A. V., Volkov, O. N., and Kovalenko, I. G. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett., 180: 47-53, 2002.
33. Haiman, C. A., Hankinson, S. E., Spiegelman, D., Colditz, G. A., Willett, W. C., Speizer, F. E., Kelsey, K. T., and Hunter, D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res., 59: 1015-1020, 1999.
34. Lin, C. J., Martens, J. W., and Miller, W. L. NF-1C, Sp1, and Sp3 are essential for transcription of the human gene for P450c17 (steroid 17α-hydroxylase/17,20 lyase) in human adrenal NCI-H295A cells. Mol. Endocrinol., 15: 1277-1293, 2001.
35. Hsing, A. W. Hormones and prostate cancer: what's next? Epidemiol. Rev., 23: 42-58, 2001.
36. Vatten, L. J., Ursin, G., Ross, R. K., Stanczyk, F. Z., Lobo, R. A., Harvei, S., and Jellum, E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomark. Prev., 6: 967-969, 1997.
37. Ostrander, E. A., and Stanford, J. L. Genetics of prostate cancer: too many loci, too few genes. Am. J. Hum. Genet., 67: 1367-1375, 2000.
38. Stanford, J. L., and Ostrander, E. A. Familial prostate cancer. Epidemiol. Rev., 23: 19-23, 2001.
39. Ye, Z., and Parry, J. M. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis, 17: 119-126, 2002.
40. Haiman, C. A., Hankinson, S. E., Colditz, G. A., Hunter, D. J., and De Vivo, I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res., 61: 3955-3960, 2001.
41. Garner, E. I., Stokes, E. E., Berkowitz, R. S., Mok, S. C., and Cramer, D. W. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res., 62: 3058-3062, 2002.
42. Spurdle, A. B., Chen, X., Abbazadegan, M., Martin, N., Khoo, S. K., Hurst, T., Ward, B., Webb, P. M., and Chenevix-Trench, G. CYP17 promotor polymorphism and ovarian cancer risk. Int. J. Cancer, 86: 436-439, 2000.
43. Yu, M. W., Yang, Y. C., Yang, S. Y., Cheng, S. W., Liaw, Y. F., Lin, S. M., and Chen, C. J. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J. Natl. Cancer Inst. (Bethesda), 93: 1644-1651, 2001.
44. Marszalek, B., Lacinski, M., Babych, N., Capla, E., Biernacka-Lukanty, J., Warenik-Szymankiewicz, A., and Trzeciak, W. H. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecol. Endocrinol., 15: 123-128, 2001.
45. Schatzl, G., Gsur, A., Bernhofer, G., Haidinger, G., Hinteregger, S., Vutuc, C., Haitel, A., Micksche, M., Marberger, M., and Madersbacher, S. Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urology, 57: 567-572, 2001.
46. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA - Cancer J. Clin., 51: 15-36, 2001.
47. Ioannidis, J. P., Ntzani, E. E., Trikalinos, T. A., and Contopoulos-Ioannidis, D. G. Replication validity of genetic association studies. Nat. Genet., 29: 306-309, 2001.